A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Status:
Terminated
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the safety of MRX34 in patients with primary liver cancer or
other selected solid tumors or hematologic malignancies. The drug is given intravenously, for
5 days in a row and then two weeks off.